Comparison Of Outcome Of Treatment OF Topical 15%TCA VS Topical 0.05% Tretinoin In Treatment Of Acanthosis Nigricans
Acanthosis Nigricans
About this trial
This is an interventional treatment trial for Acanthosis Nigricans
Eligibility Criteria
Inclusion Criteria: Patients who will present with acanthosis nigricans as per operational definition will be included in the study. Either gender. Age 20-50 years. Exclusion Criteria: Pregnancy. Breastfeeding. Patients with history of skin resurfacing by dermabrasion, chemical peels and facial laser within the preceding 9 months. Patients with history of hypersensitivity. Malignant Acanthosis Nigricans. Drug Induced Acanthosis Nigricans.
Sites / Locations
- JPMC
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group A Topical 15% Trichloroacetic acid
Group B Topical 0.05% Tretinoin
15 % Trichloroacetic acid (TCA) and 0.05%Tretinoin for 02 months Trichloroacetic acid, a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. 9-10 Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
Topical tretinoin is the first choice of drug in the treatment of acanthosis nigricans. Despite several therapeutic modalities, acanthosis nigricans (AN) remains a difficult dermatosis to treat.